surmount-1 trial tirzepatide obesity without diabetes (ZEPBOUND) Approved for Chronic Weight Management in Adults with ✨ The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults with obesity (BMI of 30 kg/ m2 or Semaglutide vs. Tirzepatide for Obesity
Description
Most users pick a consistent day and time for convenience and adherence
When you stop taking Mounjaro, the effects of the medication will wear off, and you might notice that you are getting your appetite back
Diastolic blood pressure was significantly reduced in Study 1 but not in Study 2
FDA Information on Mounjaro Mounjaro Drug Information for the official FDA label, including clinical trial results and safety details
This can help with appetite control and subsequent weight management
